F2F22F + DL001Z

F2F22F + DL001Z is a multivalent, messenger RNA (mRNA)-based seasonal influenza vaccine candidate developed by GSK. The vaccine is designed to provide protection against multiple strains of the influenza virus, typically encompassing both Influenza A (subtypes H1N1 and H3N2) and Influenza B (Victoria and Yamagata lineages). It utilizes mRNA technology to encode the hemagglutinin (HA) surface proteins of these specific viral strains. Once administered, the mRNA is translated by the recipient's cells to produce the HA antigens, which subsequently trigger a robust immune response, including the production of neutralizing antibodies and T-cell activation. This combination candidate is part of GSK's broader effort to develop next-generation, highly effective seasonal flu vaccines that can be manufactured more rapidly than traditional egg-based methods.

Other names

GSK mRNA multivalent seasonal influenza vaccine candidate